Sequenom
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Sequenom's revenues will grow 153.4% and EPS will remain in the red.
The average estimate for revenue is $46.2 million. On the bottom line, the average EPS estimate is -$0.21.
Revenue details
Last quarter, Sequenom recorded revenue of $38.5 million. GAAP reported sales were much higher than the prior-year quarter's $14.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, EPS came in at -$0.26. GAAP EPS were -$0.26 for Q1 compared to -$0.22 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 36.3%, 530 basis points better than the prior-year quarter. Operating margin was -70.2%, much better than the prior-year quarter. Net margin was -76.3%, much better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $199.3 million. The average EPS estimate is -$0.80.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 656 members out of 712 rating the stock outperform, and 56 members rating it underperform. Among 159 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 144 give Sequenom a green thumbs-up, and 15 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sequenom is buy, with an average price target of $7.00.
Looking for alternatives to Sequenom? It takes more than great companies to build a fortune for the future. Learn the basic financial habits of millionaires next door and get focused stock ideas in our free report, "3 Stocks That Will Help You Retire Rich." Click here for instant access to this free report.
- Add Sequenom to My Watchlist.
